Literature DB >> 22555854

Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Jun Shen1, Alison Boeckmann, Andrew Vick.   

Abstract

A mathematical absorption model (e.g. transit compartment model) is useful to describe complex absorption process. However, in such a model, an assumption has to be made to introduce multiple doses that a prior dose has been absorbed nearly completely when the next dose is administered. This is because the drug input cannot be determined from drug depot compartment through integration of the differential equation system and has to be analytically calculated. We propose a method of dose superimposition to introduce multiple doses; thereby eliminating the assumption. The code for implementing the dose superimposition in WinNonlin and NONMEM was provided. For implementation in NONMEM, we discussed a special case (SC) and a general case (GC). In a SC, dose superimposition was implemented solely using NM-TRAN abbreviated code and the maximum number of the doses that can be administered for any subject must be pre-defined. In a GC, a user-supplied function (FUNCA) in FORTRAN code was defined to perform dose superimposition to remove the restriction that the maximum number of doses must be pre-defined.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555854     DOI: 10.1007/s10928-012-9247-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  Application of a gamma model of absorption to oral cyclosporin.

Authors:  J Debord; E Risco; M Harel; Y Le Meur; M Büchler; G Lachâtre; C Le Guellec; P Marquet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

3.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

4.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

5.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

6.  A note on population analysis of dissolution-absorption models using the inverse Gaussian function.

Authors:  Jian Wang; Michael Weiss; David Z D'Argenio
Journal:  J Clin Pharmacol       Date:  2008-03-21       Impact factor: 3.126

7.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

8.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

9.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

10.  Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

  10 in total
  15 in total

1.  Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Authors:  Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster
Journal:  Br J Clin Pharmacol       Date:  2019-02-27       Impact factor: 4.335

2.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

3.  Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.

Authors:  Brenda Cirincione; Jeffrey Edwards; Donald E Mager
Journal:  AAPS J       Date:  2016-11-28       Impact factor: 4.009

4.  Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Authors:  Stefan S De Buck; Annamaria Jakab; Markus Boehm; Douglas Bootle; Dejan Juric; Cornelia Quadt; Timothy K Goggin
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.

Authors:  Shuhua Hu; Michael Dunlavey; Serge Guzy; Nathan Teuscher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-24       Impact factor: 2.745

6.  Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.

Authors:  R Jansson-Löfmark; K Na-Bangchang; S Björkman; F Doua; M Ashton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

7.  R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.

Authors:  Christine Falcoz; Serge Guzy; Jana Kovač; Isabel Meister; Jean Coulibaly; Somphou Sayasone; David Wesche; Yu-Wei Lin; Jennifer Keiser
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-13       Impact factor: 2.745

8.  Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Authors:  Michael J Dolton; Roger J M Brüggemann; David M Burger; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

9.  Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.

Authors:  Min Dong; Tsuyoshi Fukuda; Shareen Cox; Marij T de Vries; David K Hooper; Jens Goebel; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

10.  Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.

Authors:  Thierry Wendling; Kayode Ogungbenro; Etienne Pigeolet; Swati Dumitras; Ralph Woessner; Leon Aarons
Journal:  Pharm Res       Date:  2014-11-26       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.